학술논문
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry.
Document Type
Academic Journal
Author
Calafat M; Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.; Torres P; Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.; Tosca-Cuquerella J; Gastroenterology Department, Hospital Clínic Universitari de València, València, Spain.; Sánchez-Aldehuelo R; Gastroenterology Department, Hospital Ramón y Cajal, Madrid Spain.; Rivero M; Gastroenterology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.; Instituto de investigación IDIVAL, Santander, Spain.; Iborra M; Gastroenterology Department, Hospital Universitari i Politècnic La Fe, València, Spain.; González-Vivo M; Gastroenterology Department, Hospital del Mar, Barcelona, Spain.; Vera I; Gastroenterology Department, Hospital Universitario Puerta de Hierro, Majadahonda, Spain.; de Castro L; Gastroenterology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain.; Bujanda L; Biodonostia Health Research Institute, San Sebastián, Spain.; Universidad del País Vasco/Euskal Herriko Unibertsitatea, San Sebastián, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.; Barreiro-de Acosta M; Gastroenterology Department, Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain.; González-Muñoza C; Gastroenterology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.; Calvet X; Gastroenterology Department, Corporació Sanitària Universitària Parc Taulí, Sabadell, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.; Benítez JM; Gastroenterology Department, Hospital Universitario Reina Sofía, Córdoba, Spain.; Instituto Maimónides de Investigación Biomédica de Córdoba, Córdoba, Spain.; Llorente-Barrio M; Gastroenterology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.; Surís G; Gastroenterology Department, Hospital Universitari de Bellvitge (L' Hospitalet de Llobregat), Barcelona, Spain.; Cañete F; Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.; Arias-García L; Gastroenterology Department, Hospital Universitario de Burgos, Burgos, Spain.; Monfort D; Gastroenterology Department, Consorci Sanitari de Terrassa, Terrassa, Spain.; Castaño-García A; Gastroenterology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.; Garcia-Alonso FJ; Gastroenterology Department, Hospital Universitario Río Hortega, Valladolid, Spain.; Huguet JM; Gastroenterology Department, Hospital General Universitari de València, València, Spain.; Marín-Jímenez I; Gastroenterology Department, Hospital Gregorio Marañón, Madrid, Spain.; Lorente R; Gastroenterology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain.; Martín-Cardona A; Gastroenterology Department, Hospital Universitari Mútua Terrassa, Terrassa, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.; Ferrer JÁ; Gastroenterology Department, Hospital Universitario Fundación de Alcorcón (Madrid), Spain.; Camo P; Gastroenterology Department, Hospital General San Jorge, Huesca, Spain.; Gisbert JP; Gastroenterology Department, Hospital Universitario de La Princesa, IIS Princesa and UAM, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.; Pajares R; Gastroenterology Department, Hospital Universitario Infanta Sofía, Madrid, Spain.; Gomollón F; Gastroenterology Department, Hospital Clínico Universitario Lozano Blesa, IIS Aragón, Zaragoza, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.; Castro-Poceiro J; Gastroenterology Department, Hospital Clínic de Barcelona, Barcelona, Spain.; Morales-Alvarado J; Gastroenterology Department, Hospital General de Granollers, Granollers, Spain.; Llaó J; Gastroenterology Department, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Spain.; Rodríguez A; Gastroenterology Department, Hospital General Universitari d'Alacant, Alacant, Spain.; Rodríguez C; Gastroenterology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.; Pérez-Galindo P; Gastroenterology Department, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain.; Navarro M; Gastroenterology Department, Hospital Moisès Broggi, Sant Joan Despí, Spain.; Jiménez-García N; Gastroenterology Department, Hospital General Universitari d'Elx, Elx, Spain.; Carrillo-Palau M; Gastroenterology Department, Hospital Universitario de Canarias, La Laguna, Spain.; Blázquez-Gómez I; Gastroenterology Department, Hospital Universitario de Torrejón, Torrejón, Spain.; Sesé E; Gastroenterology Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain.; Almela P; Gastroenterology Department, Hospital General Universitari de Castelló, Castellón, Spain.; Ramírez de la Piscina P; Gastroenterology Department, Hospital Universitario de Álava, Vitoria, Spain.; Taxonera C; Gastroenterology Department, Hospital Clínico San Carlos, Madrid, Spain.; Rodríguez-Lago I; Gastroenterology Department, Hospital Universitario de Galdakao, Biocruces Bizkaia HRI, Galdakao, Spain.; Cabrinety L; Gastroenterology Department, Hospital Universitari Joan XXIII, Tarragona, Spain.; Vela M; Gastroenterology Department, Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain.; Mínguez M; Gastroenterology Department, Hospital Clínic Universitari de València, València, Spain.; Mesonero F; Gastroenterology Department, Hospital Ramón y Cajal, Madrid Spain.; García MJ; Gastroenterology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.; Instituto de investigación IDIVAL, Santander, Spain.; Aguas M; Gastroenterology Department, Hospital Universitari i Politècnic La Fe, València, Spain.; Márquez L; Gastroenterology Department, Hospital del Mar, Barcelona, Spain.; Silva Porto M; Gastroenterology Department, Hospital Universitario Puerta de Hierro, Majadahonda, Spain.; Pineda JR; Gastroenterology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain.; García-Etxebarría K; Biodonostia Health Research Institute, San Sebastián, Spain.; Universidad del País Vasco/Euskal Herriko Unibertsitatea, San Sebastián, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.; Bertoletti F; Gastroenterology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.; Brunet E; Gastroenterology Department, Corporació Sanitària Universitària Parc Taulí, Sabadell, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.; Mañosa M; Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.; Domènech E; Gastroenterology and Hepatology Department, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet s/n, Badalona, Catalonia 08916, Spain.; Departament de Medicina, Universitat Autònoma de Barcelona.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.
Source
Publisher: Sage Publications Country of Publication: England NLM ID: 101478893 Publication Model: eCollection Cited Medium: Print ISSN: 1756-283X (Print) Linking ISSN: 1756283X NLM ISO Abbreviation: Therap Adv Gastroenterol Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
1756-283X
Abstract
Background: Infliximab seems to be the most efficacious of the three available anti-TNF agents for ulcerative colitis (UC) but little is known when it is used as the second anti-TNF.
Objectives: To compare the clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in UC patients.
Design: Retrospective observational study.
Methods: Patients from the ENEIDA registry treated consecutively with infliximab and a subcutaneous anti-TNF (or vice versa), naïve to other biological agents, were identified and grouped according to the administration route of the first anti-TNF into IVi (intravenous initially) or SCi (subcutaneous initially).
Results: Overall, 473 UC patients were included (330 IVi and 143 SCi). Clinical response at week 14 was 42.7% and 48.3% in the IVi and SCi groups (non-statistically significant), respectively. Clinical remission rates at week 52 were 32.8% and 31.4% in the IVi and SCi groups (nonsignificant differences), respectively. A propensity-matched score analysis showed a higher clinical response rate at week 14 in the SCi group and higher treatment persistence in the IVi group. Regarding long-term outcomes, dose escalation and discontinuation due to the primary failure of the first anti-TNF and more severe disease activity at the beginning of the second anti-TNF were inversely associated with clinical remission.
Conclusion: The use of a second anti-TNF for UC seems to be reasonable in terms of efficacy, although it is particularly reduced in the case of the primary failure of the first anti-TNF. Whether the second anti-TNF is infliximab or subcutaneous does not seem to affect efficacy.
Competing Interests: MC has served as a speaker for Takeda, Janssen, Faes Farma, and MSD; FC has served as a speaker or has received educational grants from Takeda, Janssen, MSD, and Ferring; MR has served as a speaker or has received research or educational funding or advisory fees from MSD, Abbvie, Pfizer, Takeda, and Janssen; MI has served as a speaker or has received research or educational funding or advisory fees from MSD, Janssen, Adacyte, and Takeda; LC has served as a speaker or has received research or educational funding or advisory fees from Abbvie, Dr. Falk Pharma, and Tillots Pharma; LB has served as a speaker or has received research or educational funding or advisory fees from Ikan Biotech; MBA has served as a speaker or has received research or educational funding or advisory fees from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, Gillead, Celgene, Pfizer, Sandoz, Biogen, Fresenius, Ferring, Faes Farma, Dr. Falk Pharma, Chiesi, Gebro Pharma, Adacyte, and Vifor Pharma; CG-M has received educational funding fees from AbbVie, Janssen, Pfizer, Ferring, Kern Pharma, Norgine, and Tillots Pharma; JMH has served as a speaker or has received research or educational funding or advisory fees from Merck Sharp & Dohme, Ferring, Abbvie, Janssen, Biogen, Sandoz, Kern Pharma, Faes Farma, Vifor Pharma, and Takeda; RL has served as a speaker or has received research or educational funding or advisory fees from MSD, Abbvie, Pfizer, Takeda, Janssen, and Dr. Falk; AM-C has received research or educational funding from Abbvie, Biogen, Ferring, Janssen, MSD, Takeda, Dr. Falk Pharma, and Tillotts; JPG has served as a speaker or has received research or educational funding or advisory fees from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos, Lilly, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norgine, and Vifor Pharma; FG has served as a speaker or has received research or educational funding or advisory fees from Faes-Farma, Galápagos, Takeda, Pfizer, Janssen, and Abbvie; PA has served as a speaker or has received research or educational funding or advisory fees from MSD, Abbvie, Takeda, Janssen, Gebro Pharma, Tillotts Pharma, and Biogen; CT has served as a speaker or has received research or educational funding or advisory fees from MSD, AbbVie, Pfizer, Takeda, Janssen, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Galapagos, and Tillots; IR-L has served as a speaker or has received research or educational funding or advisory fees from MSD, Pfizer, Abbvie, Takeda, Janssen, Tillotts Pharma, Kern, Celltrion, Roche, Ferring, Dr. Falk Pharma, Galapagos, Otsuka Pharmaceutical, and Adacyte; MM has served as a speaker and has received research or educational funding from MSD, AbbVie, Takeda, Janssen, Ferring, and Pfizer; ED has served as a speaker or has received research or educational funding or advisory fees from AbbVie, Adacyte Therapeutics, Biogen, Celltrion, Galapagos, Gilead, Janssen, Kern Pharma, MSD, Pfizer, Roche, Samsung, Takeda, and Tillots; MJG has served as a speaker or has received research or educational funding or advisory fees from Janssen, Pfizer, Abbvie, Takeda, Kern Pharma, and Ferring; MA has served as a speaker or has received research or educational funding or advisory fees from Faes, Ferring, and Janssen, and received educational grants from Janssen; JRP has served as a speaker or has received research or educational funding or advisory fees from MSD, AbbVie, and Tillots Pharma; FB received educational funding fees from AbbVie, Janssen, Pfizer, Ferring, Kern Pharma, Norgine, and Tillots Pharma. The remaining authors declared no conflicts of interest.
(© The Author(s), 2024.)
Objectives: To compare the clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in UC patients.
Design: Retrospective observational study.
Methods: Patients from the ENEIDA registry treated consecutively with infliximab and a subcutaneous anti-TNF (or vice versa), naïve to other biological agents, were identified and grouped according to the administration route of the first anti-TNF into IVi (intravenous initially) or SCi (subcutaneous initially).
Results: Overall, 473 UC patients were included (330 IVi and 143 SCi). Clinical response at week 14 was 42.7% and 48.3% in the IVi and SCi groups (non-statistically significant), respectively. Clinical remission rates at week 52 were 32.8% and 31.4% in the IVi and SCi groups (nonsignificant differences), respectively. A propensity-matched score analysis showed a higher clinical response rate at week 14 in the SCi group and higher treatment persistence in the IVi group. Regarding long-term outcomes, dose escalation and discontinuation due to the primary failure of the first anti-TNF and more severe disease activity at the beginning of the second anti-TNF were inversely associated with clinical remission.
Conclusion: The use of a second anti-TNF for UC seems to be reasonable in terms of efficacy, although it is particularly reduced in the case of the primary failure of the first anti-TNF. Whether the second anti-TNF is infliximab or subcutaneous does not seem to affect efficacy.
Competing Interests: MC has served as a speaker for Takeda, Janssen, Faes Farma, and MSD; FC has served as a speaker or has received educational grants from Takeda, Janssen, MSD, and Ferring; MR has served as a speaker or has received research or educational funding or advisory fees from MSD, Abbvie, Pfizer, Takeda, and Janssen; MI has served as a speaker or has received research or educational funding or advisory fees from MSD, Janssen, Adacyte, and Takeda; LC has served as a speaker or has received research or educational funding or advisory fees from Abbvie, Dr. Falk Pharma, and Tillots Pharma; LB has served as a speaker or has received research or educational funding or advisory fees from Ikan Biotech; MBA has served as a speaker or has received research or educational funding or advisory fees from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, Gillead, Celgene, Pfizer, Sandoz, Biogen, Fresenius, Ferring, Faes Farma, Dr. Falk Pharma, Chiesi, Gebro Pharma, Adacyte, and Vifor Pharma; CG-M has received educational funding fees from AbbVie, Janssen, Pfizer, Ferring, Kern Pharma, Norgine, and Tillots Pharma; JMH has served as a speaker or has received research or educational funding or advisory fees from Merck Sharp & Dohme, Ferring, Abbvie, Janssen, Biogen, Sandoz, Kern Pharma, Faes Farma, Vifor Pharma, and Takeda; RL has served as a speaker or has received research or educational funding or advisory fees from MSD, Abbvie, Pfizer, Takeda, Janssen, and Dr. Falk; AM-C has received research or educational funding from Abbvie, Biogen, Ferring, Janssen, MSD, Takeda, Dr. Falk Pharma, and Tillotts; JPG has served as a speaker or has received research or educational funding or advisory fees from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos, Lilly, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norgine, and Vifor Pharma; FG has served as a speaker or has received research or educational funding or advisory fees from Faes-Farma, Galápagos, Takeda, Pfizer, Janssen, and Abbvie; PA has served as a speaker or has received research or educational funding or advisory fees from MSD, Abbvie, Takeda, Janssen, Gebro Pharma, Tillotts Pharma, and Biogen; CT has served as a speaker or has received research or educational funding or advisory fees from MSD, AbbVie, Pfizer, Takeda, Janssen, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Galapagos, and Tillots; IR-L has served as a speaker or has received research or educational funding or advisory fees from MSD, Pfizer, Abbvie, Takeda, Janssen, Tillotts Pharma, Kern, Celltrion, Roche, Ferring, Dr. Falk Pharma, Galapagos, Otsuka Pharmaceutical, and Adacyte; MM has served as a speaker and has received research or educational funding from MSD, AbbVie, Takeda, Janssen, Ferring, and Pfizer; ED has served as a speaker or has received research or educational funding or advisory fees from AbbVie, Adacyte Therapeutics, Biogen, Celltrion, Galapagos, Gilead, Janssen, Kern Pharma, MSD, Pfizer, Roche, Samsung, Takeda, and Tillots; MJG has served as a speaker or has received research or educational funding or advisory fees from Janssen, Pfizer, Abbvie, Takeda, Kern Pharma, and Ferring; MA has served as a speaker or has received research or educational funding or advisory fees from Faes, Ferring, and Janssen, and received educational grants from Janssen; JRP has served as a speaker or has received research or educational funding or advisory fees from MSD, AbbVie, and Tillots Pharma; FB received educational funding fees from AbbVie, Janssen, Pfizer, Ferring, Kern Pharma, Norgine, and Tillots Pharma. The remaining authors declared no conflicts of interest.
(© The Author(s), 2024.)